[Chemical radioprotectors].
Basic mechanisms of radioprotection and clinical applicability of radioprotectors for low-and high-LET radiotherapy were reviewed and discussed here. Chemical radioprotectors are able to inhibit indirect radiation damage, to repair direct and indirect damage once they occur, and to facilitate the recovery of damaged cells on depleted cell populations. The vast majority of radioprotective agents that have been developed and tested are the aminothiols. WR-2721 or ethiofos represents a significant improvement in effectiveness, potency and reduction of toxicity over the early radioprotectors. WR-151327 provided substantial protection against neutron irradiation. Dose modification factors after single doses of cyclotron neutrons were 1.5 for both early and late skin damage and 1.5-2.4 for late muscle damage.
Ando
K
K
National Institute Radiclogical Science.
D004999:Amifostine / Q000627:therapeutic use; D000818:Animals; D005260:Female; D007928:Lethal Dose 50; D051379:Mice; D008809:Mice, Inbred C3H; D009132:Muscles / Q000528:radiation effects; D009502:Neutrons; D011829:Radiation Dosage; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011837:Radiation-Protective Agents; D012867:Skin / Q000528:radiation effects
D011837:Radiation-Protective Agents; D004999:Amifostine